Advertisement

European Archives of Oto-Rhino-Laryngology

, Volume 273, Issue 12, pp 4289–4294 | Cite as

Efficacy of chlorophyll c2 for seasonal allergic rhinitis: single-center double-blind randomized control trial

  • Takashi FujiwaraEmail author
  • Naoya Nishida
  • Jumpei Nota
  • Takashi Kitani
  • Kunihide Aoishi
  • Hirotaka Takahashi
  • Takuya Sugahara
  • Naohito Hato
Rhinology

Abstract

Chlorophyll c2 extracted from Sargassum horneri improved allergic symptoms in an animal model of allergic rhinitis. In the present study, we explored the efficacy of chlorophyll c2 in patients with seasonal allergic rhinitis. This was a single-center, randomized, double-blind placebo-controlled trial. Sixty-six patients aged 20–43 years, each with a 2-year history of seasonal allergic rhinitis, were randomly assigned to receive either a single daily dose (0.7 mg) of chlorophyll c2 or placebo for 12 weeks. The use of medications including H1-antihistamines and topical nasal steroids was recorded by rescue medication scores (RMSs) noted after 4, 8, and 12 weeks of treatment. Disease-specific quality of life was measured using the Japan Rhinitis Quality of Life Questionnaire (JRQLQ) both before and after 4, 8, and 12 weeks of treatment. The RMS at 8 weeks was significantly better in the chlorophyll c2 than the placebo group (mean RMS difference = −3.09; 95 % confidence interval = −5.96 to −0.22); the mean RMS at 4 weeks was only slightly better in the chlorophyll c2 group. The JRQLQ scores did not differ significantly between the two groups. Chlorophyll c2 would have a potential to be an alternative treatment for allergic rhinitis.

Keywords

Complementary therapies Chlorophyll c2 Sargassum horneri Seaweed Allergic rhinitis 

Notes

Compliance with ethical standards

Funding

The Maruha Nichiro Corporation sponsored these trials and prepared the chlorophyll c2 and placebo capsules. The Maruha Nichiro Corporation did not have any role in the study design, data analysis, interpretation, or reporting of results.

Conflict of interest

TF declares that he has no conflict of interest. NN declares that he has no conflict of interest. JN declares that he has no conflict of interest. TT declares that he has no conflict of interest. KA declares that he has no conflict of interest. HT declares that he has no conflict of interest. TS collaborated with the Maruha Nichiro Corporation and reported some basic researches (reference No. 9 and No. 10). NH declares that he has no conflict of interest.

Research involving human participants

All procedures performed in studies involving human participants were in accordance with the guidance of clinical research by Japan Ministry of Health Labour and Welfare and with the 1964 Helsinki declaration and its later amendment ethical standards.

Informed consent

Written informed was obtained from all individual participants included in this study before trial enrollment.

References

  1. 1.
    Okubo K, Kurono Y, Fujieda S et al (2011) Japanese guideline for allergic rhinitis. Allergol Int 60:171–189. doi: 10.2332/allergolint CrossRefPubMedGoogle Scholar
  2. 2.
    Meltzer EO, Bukstein DA (2011) The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 106(2 Suppl):S12–S16. doi: 10.1016/j.anai.2010.10.014 CrossRefPubMedGoogle Scholar
  3. 3.
    Committee of Practice Guidance for management of Allergic Rhinitis (2016) Practice Guideline for the Management of Allergic Rhinitis in Japan, 8th edition [in Japanese]. Life Sci, TokyoGoogle Scholar
  4. 4.
    Ishida Y, Nakamura F, Kanzato H et al (2005) Effect of milk fermented with Lactobacillus acidophilus strain L-92 on symptoms of Japanese cedar pollen allergy: a randomized placebo-controlled trial. Biosci Biotechnol Biochem 69:1652–1660CrossRefPubMedGoogle Scholar
  5. 5.
    Cheng J, Yang XN, Liu X, Zhang SP (2006) Capsaicin for allergic rhinitis in adults. Cochrane Database Syst Rev:CD004460Google Scholar
  6. 6.
    Montaño Velázquez BB, Jáuregui-Renaud K, Bañuelos Arias Adel C et al (2006) Vitamin E effects on nasal symptoms and serum specific IgE levels in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 96:45–50CrossRefPubMedGoogle Scholar
  7. 7.
    Kim JA, Ahn BN, Kong CS, Kim SK (2012) Protective effect of chromene isolated from Sargassum horneri against UV-A-induced damage in skin dermal fibroblasts. Exp Dermatol 21:630–631. doi: 10.1111/j.1600-0625.2012.01535.x CrossRefPubMedGoogle Scholar
  8. 8.
    Airanthi MK, Hosokawa M, Miyashita K (2011) Comparative antioxidant activity of edible Japanese brown seaweeds. J Food Sci 76:C104–C111. doi: 10.1111/j.1750-3841.2010.01915.x CrossRefPubMedGoogle Scholar
  9. 9.
    Yoshioka H, Kamata A, Konishi T et al (2013) Inhibitory effect of chlorophyll c2 from brown algae, Sargassum horneri, on degranulation of RBL-2H3 cells. J Funct Foods 5:204–210. doi: 10.1016/j.jff.2012.10.006 CrossRefGoogle Scholar
  10. 10.
    Yoshioka H, Ishida M, Nishi K et al (2014) Studies on anti-allergic activity of Sargassum horneri extract. J Funct Foods 10:154–160. doi: 10.1016/j.jff.2014.06.002 CrossRefGoogle Scholar
  11. 11.
    Kuehr J, Brauburger J, Zielen S et al (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109:274–280CrossRefPubMedGoogle Scholar
  12. 12.
    Brinkhaus B, Ortiz M, Witt CM (2013) Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med 158:225–234. doi: 10.7326/0003-4819-158-4-201302190-00002 CrossRefPubMedGoogle Scholar
  13. 13.
    Okuda M, Ohkubo K, Goto M et al (2005) Comparative study of two Japanese rhinoconjunctivitis quality-of-life questionnaires. Acta Otolaryngol 125:736–744CrossRefPubMedGoogle Scholar
  14. 14.
    Fujii T, Ogino S, Arimoto H et al (2007) Correlation between the SF-8 health status questionnaire and JRQLQ in patients with Japanese cedar pollinosis. Arerugi 56:109–117PubMedGoogle Scholar
  15. 15.
    Juniper EF, Guyatt GH (1991) Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21:77–83CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Takashi Fujiwara
    • 1
    Email author
  • Naoya Nishida
    • 2
  • Jumpei Nota
    • 2
  • Takashi Kitani
    • 2
  • Kunihide Aoishi
    • 3
  • Hirotaka Takahashi
    • 4
  • Takuya Sugahara
    • 5
  • Naohito Hato
    • 2
  1. 1.Department of OtolaryngologyKurashiki Central HospitalKurashikiJapan
  2. 2.Department of Otorhinolaryngology, Head and Neck SurgeryEhime University Graduate School of MedicineToonJapan
  3. 3.Department of OtolaryngologyUwajima City Hospital, GotenmachiUwajimaJapan
  4. 4.Department of OtolaryngologyTakanoko HospitalMatsuyamaJapan
  5. 5.Department of Applied Lifescience, Faculty of AgricultureEhime UniversityMatsuyamaJapan

Personalised recommendations